How Biogen Inc. Makes Most of Its Money

Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug Tecfidera.

Drug

First-Quarter 2017 Sales

Continue reading


Source: Fool.com